alkenes has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asan, A; Braden, DC; Brown, DD; Casey, A; Chang, F; Fagunloye, A; Freeman, BA; Harkness, T; Hong, L; Lee, AV; Neumann, CA; Razzaghi, M; Salvatore, SR; Schopfer, F; Skoko, JJ; Spies, M; Straub, A; Uvalle, C; Wood, K; Woodcock, SR; Zhao, Y | 1 |
1 other study(ies) available for alkenes and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies.
Topics: Alkenes; Animals; Apoptosis; DNA; Homologous Recombination; Humans; Mice; Nitrogen Dioxide; Rad51 Recombinase; Triple Negative Breast Neoplasms | 2023 |